The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Caveman, I’m in a very similar situation to you. I’m continuing to hold as I think this is a great company with fantastic products that will sell.
I’m lucky that I don’t need to access the funds.
At the very worst I think the company will be bought out if it cannot monetise it’s pipeline.
However we have all seen what happens to the share price when there is good news.
So I’m being patient and am confident that this will come good, and some.
Andrew Marr interviewing Sir Peter Horby, chair of NERVTAG, said that despite being double- jabbbed, he contracted the coronavirus last week and that it was very unpleasant. He said that the symptoms to start with were more like a summer cold and he didn’t suspect it was covid.
Sir Peter said that the vaccines are very effective at preventing hospitalisation and deaths, but not necessarily infections.
Sir Peter also said that this winter there is increased susceptibility to flu in the population, as there was very little flu last year. And that immunity will decline over time to those vaccinated against the virus.
Putting this together I can see that testing will continue to be needed in huge numbers to keep the country going. The first sign of a cold people will be wanting to get tested. With a new health secretary in place hopefully he will use a sovereign test this time round.
Remember that dividends are paid out after tax… not sure what the capital gains tax or corporation tax is in Russia…and there’ll be all the professional fees to be paid, and money retained for working capital for the retained assets.
The company will not be paying out 100% of the sale proceeds.
But even so it will be hefty and I believe equal at least to the share price to totally derail our investments .
Hi Mike,
The Companies Act will make sure that the results of the new subsidiary are included in the EUA group accounts.
It’s very much included and transparent in law.
It’s not a stand alone company that will go under the radar.
Best, Midsummer
I believe in the strength of the whole management team, especially in the chairman who is highly qualified, talented, experienced and highly principled
We have been sailing in uncharted waters during the epidemic and getting FDA approval was an unexpected demand on the business.
In addition the skill of the scientists coming up with the AIHL test, amongst the other USPS is undervalued massively.
I believe that to be promoted by BC is unappreciated by the market at the current share price.
Once sales arrive the sky is the limit. Not only is this a fascinating investment, it is doing so much good.
I’m fully loaded on this share otherwise I would be adding at this price. I’m pretty sure it will double in a couple of heart beats once news arrives.